A. V. Burlakova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. V. Burlakova has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey E. Klimov
Peoples’ Friendship University of Russia named after Patrice Lumumba
3 shared publications - Mikhail Kosachenko
Peoples’ Friendship University of Russia named after Patrice Lumumba
3 shared publications - Aleksandr Leonovich
Peoples’ Friendship University of Russia named after Patrice Lumumba. University Clinical Hospital named after V.V. Vinogradov
2 shared publications - Alexander Alekseevich Barkhudarov
Peoples’ Friendship University of Russia named after Patrice Lumumba
2 shared publications - D. G. Safronova
Peoples’ Friendship University of Russia named after Patrice Lumumba. University Clinical Hospital named after V.V. Vinogradov
2 shared publications - E. S. Aliev
Peoples’ Friendship University of Russia named after Patrice Lumumba. University Clinical Hospital named after V.V. Vinogradov
1 shared publication
Latest Publications
- 26 March 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (1)
Indocyanine green dose ranging in laparoscopic cholecystectomy for acute calculous cholecystitis
Aim . To determine the optimal dose and timing of indocyanine green for fluorescein cholangiography in laparoscopic cholecystectomy for patients with acute calculous cholecystitis. Material and methods . From March 2024 to February 2025, a prospective, non-randomized study of indocyanine green for fluorescein cholangiography in laparoscopic cholecystectomy was conducted in 197 patients with acute cholecystitis. Various doses of indocyanine green (1.25–10 mg) were administered at various times prior to surgery: from 40 min to 6 h and intraoperatively. The fluorescence intensity, time of optimal mapping of hepatoduodenal ligament structures, and ability to safely perform surgery were assessed. Results. A dose of 5 mg indocyanine green provides an optimal effect within 3–6 h after administration. A dose of 2.5 mg indocyanine green shows the best effect within 1–3 h. When 1.25 mg of indocyanine green is administered 40–90 min before surgery, sufficient fluorescence can be achieved; however, adjustments to the equipment settings are required. Intraoperative 1.25–2.5 mg administration of the drug ensures a rapid examination of the ducts; however, accompanying hyperfluorescence hampers tissue differentiation. Conclusion . ICG fluorescence cholangiography is a safe and effective method of intraoperative navigation. Optimal doses are 2.5 and 5 mg administered 1–3 and 3–5 h before surgery, respectively. A dose of 1.25 mg may be administered pre- or intraoperatively for at least 1.5 h.
- 26 March 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (1)
Indocyanine green dose ranging in laparoscopic cholecystectomy for acute calculous cholecystitis
Aim . To determine the optimal dose and timing of indocyanine green for fluorescein cholangiography in laparoscopic cholecystectomy for patients with acute calculous cholecystitis. Material and methods . From March 2024 to February 2025, a prospective, non-randomized study of indocyanine green for fluorescein cholangiography in laparoscopic cholecystectomy was conducted in 197 patients with acute cholecystitis. Various doses of indocyanine green (1.25–10 mg) were administered at various times prior to surgery: from 40 min to 6 h and intraoperatively. The fluorescence intensity, time of optimal mapping of hepatoduodenal ligament structures, and ability to safely perform surgery were assessed. Results. A dose of 5 mg indocyanine green provides an optimal effect within 3–6 h after administration. A dose of 2.5 mg indocyanine green shows the best effect within 1–3 h. When 1.25 mg of indocyanine green is administered 40–90 min before surgery, sufficient fluorescence can be achieved; however, adjustments to the equipment settings are required. Intraoperative 1.25–2.5 mg administration of the drug ensures a rapid examination of the ducts; however, accompanying hyperfluorescence hampers tissue differentiation. Conclusion . ICG fluorescence cholangiography is a safe and effective method of intraoperative navigation. Optimal doses are 2.5 and 5 mg administered 1–3 and 3–5 h before surgery, respectively. A dose of 1.25 mg may be administered pre- or intraoperatively for at least 1.5 h.
- 20 February 2026
- Published by Media Sphere Publishing Group in Endoscopic Surgery
- Vol. 32 (1)
Advantages of minilaparoscopic access in comparison with standard laparoscopic access during cholecystectomy
Objective. The aim of the study was to evaluate the advantages of access and the use of needlescopic instruments with a diameter of 3 mm in comparison with traditional laparoscopic access during cholecystectomy. Material and methods. The study was performed at the Department of Faculty Surgery of the RUDN Medical Institute on the basis of the V.V. Vinogradov Clinical Hospital. The prospective follow-up included 46 patients hospitalized at the V.V. Vinogradov Clinical Hospital as planned with a diagnosis of cholelithiasis. The average age of the study group was 57.4 ±15.3 years, 65% of women, 5 patients previously had biliary tract surgery. During the first five months of the study, 23 patients underwent mini-laparoscopic cholecystectomy (MLC) and were considered the main study group. Over the next five months, a control group was collected, it included 23 patients with cholelithiasis, who underwent cholecystectomy with traditional laparoscopic access. Results. The average duration of the operation in the main group was 52.8±14.8 minutes, in the control group 45.4±14.5 minutes, but this difference did not reach statistical significance (p>0.05). There were no intraoperative complications of surgical intervention in any of the groups. There was a tendency to reduce the length of hospital stay in the main group: the average bed-day in the main group was 3.3±0.8 bed-days, in the control group 3.8±1.2 bed-days (p>0.05). In the main group, the pain syndrome (assessed on a visual analog scale (VAS) from 0 to 10 points) in the early postoperative period was less pronounced than in the control group, while every fourth patient in the MLC group had no pain syndrome. Conclusion. Minilaparoscopic cholecystectomy is associated with less pronounced pain syndrome in the early postoperative period. Early activation of patients became feasible. Further, MLC reduced need for nonsteroidal anti-inflammatory drugs, shorter hospital stays, and hence the duration of temporary disability. Moreover, MLC showed better cosmetic results in the long term. Thus, if technically possible, preference should be given to minimally invasive interventions, especially in patients of working age.
- 20 February 2026
- Published by Media Sphere Publishing Group in Endoscopic Surgery
- Vol. 32 (1)
Advantages of minilaparoscopic access in comparison with standard laparoscopic access during cholecystectomy
Objective. The aim of the study was to evaluate the advantages of access and the use of needlescopic instruments with a diameter of 3 mm in comparison with traditional laparoscopic access during cholecystectomy. Material and methods. The study was performed at the Department of Faculty Surgery of the RUDN Medical Institute on the basis of the V.V. Vinogradov Clinical Hospital. The prospective follow-up included 46 patients hospitalized at the V.V. Vinogradov Clinical Hospital as planned with a diagnosis of cholelithiasis. The average age of the study group was 57.4 ±15.3 years, 65% of women, 5 patients previously had biliary tract surgery. During the first five months of the study, 23 patients underwent mini-laparoscopic cholecystectomy (MLC) and were considered the main study group. Over the next five months, a control group was collected, it included 23 patients with cholelithiasis, who underwent cholecystectomy with traditional laparoscopic access. Results. The average duration of the operation in the main group was 52.8±14.8 minutes, in the control group 45.4±14.5 minutes, but this difference did not reach statistical significance (p>0.05). There were no intraoperative complications of surgical intervention in any of the groups. There was a tendency to reduce the length of hospital stay in the main group: the average bed-day in the main group was 3.3±0.8 bed-days, in the control group 3.8±1.2 bed-days (p>0.05). In the main group, the pain syndrome (assessed on a visual analog scale (VAS) from 0 to 10 points) in the early postoperative period was less pronounced than in the control group, while every fourth patient in the MLC group had no pain syndrome. Conclusion. Minilaparoscopic cholecystectomy is associated with less pronounced pain syndrome in the early postoperative period. Early activation of patients became feasible. Further, MLC reduced need for nonsteroidal anti-inflammatory drugs, shorter hospital stays, and hence the duration of temporary disability. Moreover, MLC showed better cosmetic results in the long term. Thus, if technically possible, preference should be given to minimally invasive interventions, especially in patients of working age.
- Open Access
- 28 June 2025
- Published by ECO-Vector LLC in Journal of Clinical Practice
Optimization of fluorescence imaging with ICG in calculous cholecystitis
Optimization of fluorescence imaging with ICG in calculous cholecystitis Оптимизация флуоресцентной визуализации с ICG при калькулезном холецистите
- 28 June 2025
- Published by ECO-Vector LLC in Journal of Clinical Practice
Open AccessOptimization of fluorescence imaging with ICG in calculous cholecystitis
Optimization of fluorescence imaging with ICG in calculous cholecystitis Оптимизация флуоресцентной визуализации с ICG при калькулезном холецистите